- Quidel recorded its best-ever revenue performance in 2021 at $1.699 billion despite its gross profit falling to $1.271 billion YOY.
- The fairly priced QuickVue At-Home OTC gave Quidel the impetus to enter retail and the home Covid-19 testing market.
- Reimbursement policies by third-party insurers will contribute to headwinds needed to spur revenue growth of the company.
- Quidel is already moving to a post-Covid future by expanding its pathogen-detecting system through the Savanna MDx.
For further details see:
Quidel: A Pure-Play Point-Of-Care Solution Worth A Look